Analyzing the Price-to-Earnings Ratio of Sana Biotechnology Inc (SANA)

The 36-month beta value for SANA is also noteworthy at 1.61. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for SANA is 117.93M, and at present, short sellers hold a 20.92% of that float. The average trading volume of SANA on April 03, 2024 was 3.48M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

SANA) stock’s latest price update

Sana Biotechnology Inc (NASDAQ: SANA)’s stock price has dropped by -12.85 in relation to previous closing price of 10.12. Nevertheless, the company has seen a loss of -2.97% in its stock price over the last five trading days. 24/7 Wall Street reported 2024-02-18 that The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company’s shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.

SANA’s Market Performance

Sana Biotechnology Inc (SANA) has seen a -2.97% fall in stock performance for the week, with a -21.74% decline in the past month and a 116.18% surge in the past quarter. The volatility ratio for the week is 6.67%, and the volatility levels for the past 30 days are at 8.41% for SANA. The simple moving average for the last 20 days is -6.23% for SANA’s stock, with a simple moving average of 58.86% for the last 200 days.

Analysts’ Opinion of SANA

Many brokerage firms have already submitted their reports for SANA stocks, with H.C. Wainwright repeating the rating for SANA by listing it as a “Buy.” The predicted price for SANA in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on January 16, 2024 of the current year 2024.

JMP Securities, on the other hand, stated in their research note that they expect to see SANA reach a price target of $9. The rating they have provided for SANA stocks is “Mkt Outperform” according to the report published on September 25th, 2023.

Citigroup gave a rating of “Buy” to SANA, setting the target price at $8 in the report published on September 05th of the previous year.

SANA Trading at 10.35% from the 50-Day Moving Average

After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.50% of loss for the given period.

Volatility was left at 8.41%, however, over the last 30 days, the volatility rate increased by 6.67%, as shares sank -6.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +74.31% upper at present.

During the last 5 trading sessions, SANA fell by -2.97%, which changed the moving average for the period of 200-days by +40.00% in comparison to the 20-day moving average, which settled at $9.37. In addition, Sana Biotechnology Inc saw 116.18% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SANA starting from Yang Patrick Y, who sale 25,000 shares at the price of $9.45 back on Mar 08 ’24. After this action, Yang Patrick Y now owns 149,250 shares of Sana Biotechnology Inc, valued at $236,300 using the latest closing price.

NELSEN ROBERT, the Director of Sana Biotechnology Inc, purchase 1,818,181 shares at $5.50 during a trade that took place back on Feb 08 ’24, which means that NELSEN ROBERT is holding 12,446,022 shares at $9,999,996 based on the most recent closing price.

Stock Fundamentals for SANA

The total capital return value is set at -0.56. Equity return is now at value -72.00, with -40.81 for asset returns.

Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.44. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 144.84.

Currently, EBITDA for the company is -294.94 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.31.

Conclusion

In summary, Sana Biotechnology Inc (SANA) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts